Drug Trial Radar · NCT04686916
Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 30, 2020
Primary completion
Jul 30, 2023
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- Initiator PharmaIndustry
- Sponsor type
- Industry
- First posted
- Dec 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIa, randomised, double-blind, placebo-controlled, 3-period, crossover study to assess two single oral dose levels of IP2018. It is planned to enrol 24 patients. Patients will take part in three treatment periods, in which they will be randomised to receive either a single dose of IP2018 or a single dose of placebo in each treatment period.
Conditions
- Erectile Dysfunction
Interventions
IP2018Drug
Test drug
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Erectile FunctionTime frame: A 6 hours time interval after dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MAC
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.